ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.58995
-0.07%
Brent Oil
83.655
0.07%
Bitcoin
66,939.67
1.18%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Perspective Therapeutics Inc (CATX)

  7. Perspective Therapeutics Inc (CATX) Noticias

CATX

Perspective Therapeutics (CATX)

Perspective Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:CATX
FechaHoraFuenteTítuloSímboloCompañía
15/05/202406:00GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsAMEX:CATXPerspective Therapeutics Inc
03/05/202406:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming May Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
02/05/202406:00GlobeNewswire Inc.Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
30/04/202406:00GlobeNewswire Inc.Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsAMEX:CATXPerspective Therapeutics Inc
08/04/202407:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming April Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
28/03/202406:30GlobeNewswire Inc.Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsAMEX:CATXPerspective Therapeutics Inc
18/03/202407:00GlobeNewswire Inc.Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic MelanomaAMEX:CATXPerspective Therapeutics Inc
11/03/202407:00GlobeNewswire Inc.Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024AMEX:CATXPerspective Therapeutics Inc
05/03/202407:00GlobeNewswire Inc.Perspective Therapeutics Acquires CGMP-Compliant Manufacturing FacilityAMEX:CATXPerspective Therapeutics Inc
04/03/202408:45GlobeNewswire Inc.Perspective Therapeutics Announces $87.4 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
26/02/202407:00GlobeNewswire Inc.Perspective Therapeutics to Participate at Upcoming Investor ConferencesAMEX:CATXPerspective Therapeutics Inc
12/02/202407:00GlobeNewswire Inc.Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceAMEX:CATXPerspective Therapeutics Inc
22/01/202415:05GlobeNewswire Inc.Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
18/01/202406:00GlobeNewswire Inc.Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private PlacementAMEX:CATXPerspective Therapeutics Inc
17/01/202415:05GlobeNewswire Inc.Perspective Therapeutics Announces Proposed Public OfferingAMEX:CATXPerspective Therapeutics Inc
17/01/202407:00GlobeNewswire Inc.Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01AMEX:CATXPerspective Therapeutics Inc
09/01/202415:10AllPennyStocks.comAnother Healthcare Stock Stealing The ShowAMEX:CATXPerspective Therapeutics Inc
09/01/202407:00GlobeNewswire Inc.Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective TherapeuticsAMEX:CATXPerspective Therapeutics Inc
09/01/202407:00GlobeNewswire Inc.Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing CapabilityAMEX:CATXPerspective Therapeutics Inc
05/01/202407:00GlobeNewswire Inc.Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer TreatmentAMEX:CATXPerspective Therapeutics Inc
02/01/202407:00GlobeNewswire Inc.Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceAMEX:CATXPerspective Therapeutics Inc
12/12/202307:00GlobeNewswire Inc.Perspective Therapeutics Divests Brachytherapy BusinessAMEX:CATXPerspective Therapeutics Inc
07/12/202307:00GlobeNewswire Inc.Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine TumorsAMEX:CATXPerspective Therapeutics Inc
14/06/202315:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:CATXPerspective Therapeutics Inc
14/06/202315:42Edgar (US Regulatory)Specialized Disclosure Report (sd)AMEX:CATXPerspective Therapeutics Inc
15/05/202316:23Edgar (US Regulatory)Quarterly Report (10-q)AMEX:CATXPerspective Therapeutics Inc
15/05/202316:16Edgar (US Regulatory)Current Report Filing (8-k)AMEX:CATXPerspective Therapeutics Inc
01/05/202316:04Edgar (US Regulatory)Annual Transition Report (10-kt)AMEX:CATXPerspective Therapeutics Inc
17/03/202316:09Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)AMEX:CATXPerspective Therapeutics Inc
14/03/202307:17PR Newswire (US)Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer careAMEX:CATXPerspective Therapeutics Inc
 Showing the most relevant articles for your search:AMEX:CATX

Su Consulta Reciente

TG
HDG0
Morella
EU
DEXB
Dexia
BIT
P1X9K4
NLBNPIT1X9K4 20991231 19...
EU
NACON
Nacon
COIN
VETHHHETH
Voucher Ethereum
COIN
BPLCUSD
BlackPearl Token
LSE
JUSD
Jpm Act Us Eq D
NASDAQ
TATTF
Tat Technologies
USOTC
JWLLF
Jamieson Wellness (PK)
NASDAQ
NYMTL
New York Mortgage
LSE
PMI
Premier Miton
EU
CRHBG
Caisse de Refinancement ...
EU
VLA
Valneva
DGFX
HIVEUSDT
Hive
NASDAQ
LCAPU
Lionheart Acquisition Co...
COIN
HIGHBTC
Highstreet token
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados